Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: DEFINITY

« Back to Dashboard
Definity is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are four patents protecting this drug.

This drug has one hundred and eight patent family members in thirty countries.

The generic ingredient in DEFINITY is perflutren. One supplier is listed for this compound. Additional details are available on the perflutren profile page.

Summary for Tradename: DEFINITY

Suppliers / Packagers: see list3

Pharmacology for Tradename: DEFINITY

Clinical Trials for: DEFINITY

A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice
Status: Completed Condition: Cardiovascular Disease

Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Terminated Condition: Liver Tumors

A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure
Status: Completed Condition: Pulmonary Heart Disease

3-D Transcranial Ultrasound Analysis Study
Status: Completed Condition: Cerebrovascular Accident; Intracranial Hypertension

Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography
Status: Completed Condition: Pulmonary Arterial Hypertension

Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
Status: Completed Condition: Kidney Cancer

Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy
Status: Recruiting Condition: Breast Cancer

Definity for Ultrasound of Intraocular Tumors
Status: Recruiting Condition: Ocular Melanoma

Contrast Enhanced Endoscopic Ultrasound for Vascular Involvement in Pancreatic Lesions
Status: Withdrawn Condition: Pancreatic Tumors

Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy
Status: Active, not recruiting Condition: Breast Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYes5,527,521<disabled>Y <disabled>
Lantheus Medcl
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYes8,658,205<disabled>Y <disabled>
Lantheus Medcl
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYes6,033,645<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: DEFINITY

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,773,696 Contrast agent comprising low density microspheres<disabled in preview>
5,874,062 Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents<disabled in preview>
6,117,414 Method of computed tomography using fluorinated gas-filled lipid microspheres as contract agents<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DEFINITY

Country Document Number Publication Date
European Patent Office0580726Aug 20, 2008
World Intellectual Property Organization (WIPO)9913919Mar 25, 1999
European Patent Office0930844Sep 03, 2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn